Literature DB >> 21755505

Response to treatment in patients with Lewis-Sumner syndrome.

Shahram Attarian1, Annie Verschueren, Jérome Franques, Emmanuelle Salort-Campana, Elisabeth Jouve, Jean Pouget.   

Abstract

INTRODUCTION: Our aim was to document the classification of Lewis-Sumner syndrome (L-SS) based on the response to treatment and the pattern of progression over time.
METHODS: We retrospectively identified 15 patients with L-SS treated for at least 12 months.
RESULTS: After 1 year, intravenous immunoglobulin was effective in 7 patients, 6 were stable, and 2 worsened. After 5 years, 5 patients had improved, and 3 were stable. These 8 patients needed repeated treatment, and 2 patients gradually worsened. Two patients worsened dramatically after steroid treatment. In 3 patients the neuropathy progressed to the other limbs and developed into an asymmetric polyneuropathy. In 12 other patients the pattern remained multifocal and asymmetric.
CONCLUSIONS: The possibility of decline resulting from corticosteroids, and the fact that no neurological progression toward a diffuse pattern was observed in the majority of patients suggests that L-SS is a different entity from chronic inflammatory demyelinating polyradiculoneuropathy.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21755505     DOI: 10.1002/mus.22024

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  3 in total

1.  A case of steroid-responsive MADSAM with late appearance of a partial conduction block in the forearm.

Authors:  Shun Yoshida; Akio Kikuchi; Maki Tateyama; Ohito Tano; Ayumi Nishiyama; Tetsuya Akaishi; Masaaki Kato; Masashi Aoki
Journal:  J Neurol       Date:  2014-02-26       Impact factor: 4.849

Review 2.  Immunotherapy in Peripheral Neuropathies.

Authors:  Jean-Marc Léger; Raquel Guimarães-Costa; Cristina Muntean
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 3.  Individualized immunoglobulin therapy in chronic immune-mediated peripheral neuropathies.

Authors:  Jeffrey A Allen; Melvin Berger; Luis Querol; Krista Kuitwaard; Robert D Hadden
Journal:  J Peripher Nerv Syst       Date:  2018-04-19       Impact factor: 3.494

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.